This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal, gastric and pancreatic cancer.
OVERVIEW OF ACTIVITY
Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in the United States, accounting for approximately 8% of all cancer deaths. Although individually less frequently encountered, the collection of noncolorectal gastrointestinal (GI) cancers account for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined.
Two noncolorectal GI tumors in particular — gastric and pancreatic cancer — have witnessed several recent advances that have drastically altered current treatment considerations and approaches. As such, educational opportunities relevant to the clinical management of colorectal, gastric and pancreatic cancers are essential for medical oncologists responsible for delivering comprehensive care.
These video proceedings from a CME symposium held during the 2015 ASCO Annual Meeting feature discussions with leading researchers with an expertise in colorectal, gastric and pancreatic cancer regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to not only improve clinicians’ knowledge of recent data related to the rapidly evolving GI cancer treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers.
LEARNING OBJECTIVES
- Coordinate comprehensive biomarker analysis for patients diagnosed with advanced colorectal cancer (CRC), and use this information to guide evidence-based care.
- Communicate the benefits and risks of approved anti-VEGF, anti-EGFR and other targeted biologic therapies to patients with metastatic CRC, and develop an evidence-based algorithm to sequence these available options based on disease- and patient-specific characteristics.
- Individualize local and systemic treatment for patients with metastatic CRC that is isolated to the liver.
- Implement a clinical plan for the management of advanced HER2-positive gastric cancer, incorporating existing and emerging targeted treatments.
- Appreciate available clinical research data documenting the efficacy of ramucirumab in advanced gastric or gastroesophageal junction cancer, and discern how this agent can be optimally integrated into clinical practice for patients with HER2-negative and HER2-positive disease.
- Appraise the rationale for and clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in patients with gastric cancer.
- Consider age, performance status and other clinical factors in the selection of systemic therapy for patients with metastatic pancreatic adenocarcinoma (PAD).
- Appreciate available safety and efficacy data with nanoparticle albumin-bound (nab) paclitaxel in combination with gemcitabine, and develop effective strategies to appropriately integrate this regimen into the management of metastatic PAD.
- Describe the proposed mechanism of action and available research data with ruxolitinib in pancreatic cancer, and use this information to counsel appropriate patients regarding ongoing trials evaluating this novel approach.
- Recall new data with other investigational agents demonstrating promising activity in colorectal, gastric and pancreatic cancers.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Peter C Enzinger, MD
Director, Center for Esophageal and Gastric Cancer
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Consulting Agreements: Amgen Inc, Five Prime Therapeutics Inc, Pfizer Inc, Sirtex Medical Ltd, Taiho Oncology Inc.
Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota
Contracted Research: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Lilly, Pfizer Inc, Sanofi.
J Randolph Hecht, MD
Professor of Clinical Medicine
Carol and Saul Rosenzweig Chair in Cancer Therapies Development
Director, UCLA GI Oncology Program
Santa Monica, California
Consulting Agreements: Amgen Inc, Genentech BioOncology, Sanofi.
Eileen M O’Reilly, MD
Associate Director
Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Medical College of Cornell University
New York, New York
Consulting Agreements: Abbott Laboratories, Aduro Biotech, Amgen Inc, Astellas Scientific and Medical Affairs Inc, Celgene Corporation, Celsion Corporation, Chugai Pharmaceutical Co Ltd, Cipla Ltd, EntreMed Inc, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, IntegraGen, Jennerex Inc, Lilly, MedImmune Inc, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi, Silenseed Ltd, Vicus Therapeutics; Contracted Research: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Momenta Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Polaris Group, Roche Laboratories Inc, Vicus Therapeutics.
Philip A Philip, MD, PhD
Professor of Oncology and Medicine
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
Advisory Committee: Celgene Corporation, Halozyme Therapeutics, Novartis Pharmaceuticals Corporation; Consulting Agreement: Merck; Contracted Research: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Karyopharm Therapeutics, Lilly, Novartis Pharmaceuticals Corporation; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Sanofi.
Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospital Gasthuisberg/Leuven
Leuven, Belgium
Consulting Agreements: Bayer HealthCare Pharmaceuticals, Lilly; Research Grants: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Merck Serono, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Incyte Corporation, Lilly and Taiho Oncology Inc.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: September 2015
Expiration date: September 2016